FoxP3+, and not CD25+, T cells increase post-transplant in islet allotransplant recipients following anti-CD25+ rATG immunotherapy.
Cell Immunol
; 274(1-2): 83-8, 2012.
Article
em En
| MEDLINE
| ID: mdl-22364726
ABSTRACT
Anti-CD25 antibodies are used as an induction therapy in islet allotransplantation for type 1 diabetes. Although previous reports suggested that anti-CD25 treatment may lead to depletion of CD4+CD25+ regulatory T cells (Tregs) and questioned its use in tolerance-promoting protocols for transplantation, the effect of anti-CD25 antibodies on the frequency and function of Tregs remains unclear. We examined the effect of anti-CD25 antibody, daclizumab, in vivo on Tregs in islet allograft recipients enrolled in a single-center study and monitored post-transplant. Our data shows that the reduction in CD25+ Treg cells observed post-transplant is due to masking of CD25 receptor by daclizumab and not due to depletion. In addition, using Treg marker, FoxP3, we show that anti-CD25+ ATG treatment leads to an increase in FoxP3+ Tregs post-transplant. These data suggest that anti-CD25-based therapy has beneficial effects on Tregs and combined with ATG may be a promising therapy for autoimmunity and transplantation.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Autoanticorpos
/
Imunoglobulina G
/
Transplante das Ilhotas Pancreáticas
/
Linfócitos T Reguladores
/
Fatores de Transcrição Forkhead
/
Subunidade alfa de Receptor de Interleucina-2
/
Anticorpos Monoclonais Humanizados
/
Soro Antilinfocitário
Tipo de estudo:
Guideline
Limite:
Humans
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article